Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: A collaborative analysis of treatment programs

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 608-616

  Davies, Mary Ann ^a   May, Margaret ^b   Bolton Moore, Carolyn ^c,d   Chimbetete, Cleophas ^e   Eley, Brian ^f   Garone, Daniela ^g   Giddy, Janet ^h   Moultrie, Harry ^i,j   Ndirangu, James ^k   Phiri, Sam ^l,m   Rabie, Helena ⁿ   Technau, Karl Günter ^o   Wood, Robin ^f   Boulle, Andrew ^a   Egger, Matthias ^a,p   Keiser, Olivia ^p  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Newlands Clinic   (Zimbabwe)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

^h MCCORD HOSPITAL   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k UNIVERSITY OF KWAZULU NATAL   (South Africa)

^l KAMUZU CENTRAL HOSPITAL   (Malawi)

^m LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

ⁿ STELLENBOSCH UNIVERSITY   (South Africa)

^o UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^p UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

antiretroviral; children; HIV 1; Mortality; sub Saharan Africa

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT;

ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALAWI; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SOUTH AFRICA; ZAMBIA; ZIMBABWE; AFRICA; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; ISOLATION AND PURIFICATION; MORTALITY; NEWBORN; PRESCHOOL CHILD; TREATMENT OUTCOME;

AFRICA, SOUTHERN; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84901489224     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000214     Document Type: Article

References (47)

1. WHO. GLOBAL HIV/AIDS RESPONSE. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. 2011; Available at: http://whqlibdoc.who.int/publications/2011/9789241502986-eng.pdf. Accessed July 20 2012.
2. Anglaret X Minga A Gabillard D et al.; ANRS 12222 Morbidity/Mortality Study Group. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretrovira l therapy in Cote d'Ivoire. Clin Infect Dis. 2012;54:714-723.
3. Davies MA Keiser O Technau K et al.; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaborati on. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730-737.
4. Bolton-Moore C Mubiana-Mbewe M Cantrell R A et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899. (Pubitemid 350005233)
5. Sutcliffe CG van Dijk JH Bolton C et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489. (Pubitemid 352005822)
6. Dunn D; HIV Paediatric Prognostic Markers Collabora tive Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611. (Pubitemid 37443527)
7. Dunn D Woodburn P Duong T et al.; HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS); Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before th e availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398-404. (Pubitemid 351263421)
8. Patel K Weinberg GA Buchacz K et al. Simple Pediatric AIDS Severity Sc ore (PASS): a pediatric severity score for resource-limited settings. J Acquir Immune Defic Syndr. 2006;43:611-617. (Pubitemid 44885630)
9. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers f or predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008;22:97-105.
10. Egger M May M Chê ne G et al.; ART Cohort Collaboration. Prognosi s of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
11. May M Boulle A Phiri S et al.; IeDEA Sout hern Africa and West Africa. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
12. May M Sterne JA Sabin C et al.; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1 197. (Pubitemid 46763289)
13. The KIDS-ART-LINC Collaboration. Low risk of death but substantial program attrition in pediatric treatment cohorts in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2008 15 523-531.
14. Fassinou P Elenga N Rouet F et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan Côte d'Ivoire. AIDS. 2004;18:1905-1913. (Pubitemid 39313206)
15. Eley B Davies MA Apolles P et al. Antiretroviral treatment for children. S Afr Med J. 2006;96(9 pt 2):988-993.
16. Davies MA Egger M Keiser O et al. Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studies. Afr J AIDS Res. 2009;8:329-338.
17. Peacock-Villada E Richardson BA John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics. 2011;127:e423-e441.
18. W alker AS Prendergast AJ Mugyenyi P et al.; DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55:1707-1718.
19. Brady MT Oleske JM Williams PL et al.; Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94.
20. Fenner L Brinkhof MW Keiser O et al.; International epidemiologic Databases to Evaluate AIDS in Southern Africa. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr. 2010;54:524-532.
21. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children . Guidelines for the use of antiretroviral agents in pediatric HIV Infection. 2011; Available at http://aidsinfo.nih.gov/ContentFiles/ PediatricGuidelines.pdf. Accessed September 1 2012.
22. Musoke PM Young AM Owor MA et al. Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2008;49:171-178.
23. Egger M Ekouevi DK Williams C et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41:1256-1264.
24. WHO. The WHO child growth standard s. 2006; Available at: http://www.who.int/childgrowth/en/. Accessed November 23 2008.
25. Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0 December 2004; Clarification August 2009. 2009. Available at: http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric- Adverse-Events.pdf. Accessed January 2 2012.
26. Royston P. Multiple imputation of missing values. Stata J. 2004;4:227-241.
27. Royston P. Multiple imputation of missing values: further update of ice with an emphasis on interval censoring. Stata J. 2009;7:445-464.
28. Sterne JA White IR Carlin JB et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
29. White IR Royston P Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377-399.
30. Royston P Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002; 21:2175-2197. (Pubitemid 34830755)
31. May M Royston P Egger M et al.; ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treate d with antiretroviral therapy. Stat Med. 2004;23:2375-2398. (Pubitemid 39136248)
32. Royston P Parmar MK Sylvester R. Construction and validation of a prognostic model across several studies with an application in superfic ial bladder cancer. Stat Med. 2004;23:907-926. (Pubitemid 38344230)
33. Royston P Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004;23:723-748. (Pubitemid 38279510)
34. Royston P. Explained variation for survival models. Stata J. 2006;6: 83-96. (Pubitemid 43708445)
35. Eley B Nuttall J. Antiretroviral therapy for children: challenges and opportunities. Ann Trop Paediatr. 2007;27:1-10. (Pubitemid 350010535)
36. Braitstein P Songok J Vreeman RC et al. " Wamepotea" (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57:e40-e46.
37. Weigel R Hochgesang M Brinkhof MW et al. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe Malawi. BMC Infect Dis. 2011;11:31.
38. Leroy V Malateste K Rabie H et al.; International IeDEA Pediatric Working Group1. Outcomes of antiretroviral therapy in c hildren in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr. 2013;62:208-219.
39. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. 2010. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/ en/index.html. Accessed October 19 2010.
40. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013 Available at: http://www.who.int/ hiv/topics/treatment/technical/en/index.html. Accessed September 12 2013.
41. Violari A Cotton MF Gibb DM et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
42. Fat ti G Bock P Eley B et al. Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa 2004-2009. J Acquir Immune Defic Syndr. 2011;58:e60-e67.
43. Davies MA Phiri S Wood R et al. Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration. PLoS One. 2013;8:e81037.
44. Davies MA Moultrie H Eley B et al.; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Virologic failure and second-line antiretroviral therapy in children in South Africa-th e IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278.
45. Duggan C Fawzi W. Micronutrients and child health: studies in international nutrition and HIV infection. Nutr Rev. 2001;59:358-369. (Pubitemid 33055147)
46. Walker AS Mulenga V Ford D et al.; CHAP Team. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis. 2007;44:1361-1367. (Pubitemid 46717300)
47. Violari A Lindsey JC Hughes MD et al. Nevirapine versus ritonavirboosted lopinavir for HIV-infected children. N Engl J Med. 2012;366: 2380-2389. Diseases